Clinical Trial Update: Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) Patients Receiving Erythropoietic Agents [Phase 4]

View source ↗

Summary

Phase 4 trial comparing intravenous Ferrlecit (iron sucrose) vs oral iron in iron-deficient patients with chronic kidney disease receiving erythropoietic agents…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Iron Deficiency Anemia

Drugs mentioned

• FERRLECIT (SODIUM FERRIC GLUCONATE COMPLEX)
• Oral iron (ferrous sulfate)

Snippet

Sponsor: Watson Pharmaceuticals | Conditions: Anemia, Iron-Deficiency, Kidney Failure, Chronic | Phase 4 | Status: COMPLETED | Results posted: 2012-03-29